The BZLF1 homolog of an Epstein-Barr-related gamma-herpesvirus is a frequent target of the CTL response in persistently infected rhesus macaques

The Journal of Immunology : Official Journal of the American Association of Immunologists
M H FoggAmitinder Kaur

Abstract

Although CD8(+) T lymphocytes targeting lytic infection proteins dominate the immune response to acute and persistent EBV infection, their role in immune control of EBV replication is not known. Rhesus lymphocryptovirus (rhLCV) is a gamma-herpesvirus closely related to EBV, which establishes persistent infection in rhesus macaques. In this study, we investigated cellular immune responses to the rhLCV BZLF1 (rhBZLF1) homolog in a cohort of rhLCV-seropositive rhesus macaques. rhBZLF1-specific IFN-gamma ELISPOT responses ranging between 56 and 3070 spot-forming cells/10(6) PBMC were detected in 36 of 57 (63%) rhesus macaques and were largely mediated by CD8(+) T lymphocytes. The prevalence and magnitude of ELISPOT responses were greater in adult (5-15 years of age) rather than juvenile macaques (<5 years of age), suggesting that rhBZLF1-specific CTL increase over time following early primary infection. A highly immunogenic region in the carboxyl terminus of the rhBZLF1 protein containing overlapping CTL epitopes restricted by Mamu-A*01 and other as yet unidentified MHC class I alleles was identified. The presence of a robust CD8(+) T lymphocyte response targeting this lytic infection protein in both rhesus macaques and humans sugg...Continue Reading

References

Sep 15, 1986·International Journal of Cancer. Journal International Du Cancer·S R RanganB J Gormus
Jan 1, 1988·Proceedings of the National Academy of Sciences of the United States of America·Y ShimizuR DeMars
Nov 1, 1996·The Journal of Experimental Medicine·E ScotetE Houssaint
Dec 16, 1998·Journal of Virology·I V Redchenko, A B Rickinson
Nov 22, 2000·The Journal of Immunology : Official Journal of the American Association of Immunologists·J SidneyA Sette
Oct 24, 2001·Biomedicine & Pharmacotherapy = Biomédecine & Pharmacothérapie·E HoussaintM Bonneville
Sep 10, 2002·The Journal of Immunology : Official Journal of the American Association of Immunologists·Thorsten MühlUlrike Sauermann
Jun 24, 2005·The Journal of Immunology : Official Journal of the American Association of Immunologists·Heather D Hickman-MillerWilliam H Hildebrand

❮ Previous
Next ❯

Citations

Mar 8, 2008·ILAR Journal·Lynn M Wachtman, Keith G Mansfield
Jun 3, 2009·The Journal of Experimental Medicine·Till StrowigChristian Münz
Mar 8, 2008·ILAR Journal·Murray B Gardner, Paul A Luciw
Feb 13, 2009·Proceedings of the National Academy of Sciences of the United States of America·Mark H FoggFred Wang
Jun 10, 2009·Immunology and Cell Biology·Hui Yee GreenawayVanessa Venturi
Nov 20, 2008·Proceedings of the National Academy of Sciences of the United States of America·Yoon-Jae SongElliott Kieff
Nov 22, 2013·Journal of Virology·Rebecca L SkalskyBryan R Cullen

❮ Previous
Next ❯

Related Concepts

Related Feeds

Aminoglycosides

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.

Aminoglycosides (ASM)

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.